HK Innoen Completes Recruitment for Domestic Phase 3 Trial of GLP-1 Obesity Treatment

Conducted at 24 Medical Institutions Nationwide

On January 22, HK Innoen announced that it has completed recruitment of participants for the domestic Phase 3 clinical trial of 'IN-B00009 (ingredient name: ecnoglutide)', an obesity treatment belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class.

HK Innoen logo image. HK Innoen

This clinical trial received approval for its Phase 3 clinical trial plan (IND) from the Ministry of Food and Drug Safety in May last year, and began enrolling its first participant in September of the same year. Within approximately four months, the target number of 313 participants was successfully recruited.

The Phase 3 trial is being conducted at 24 medical institutions in Korea, including Kangbuk Samsung Hospital, targeting adult patients with obesity or overweight without diabetes. Participants will receive either IN-B00009 or a placebo as a subcutaneous injection once a week for 40 weeks, with the effects on weight loss and safety being evaluated. The primary endpoints are the percentage change in body weight at week 40 compared to baseline and the proportion of participants achieving at least a 5% reduction in body weight.

IN-B00009 is a substance introduced by HK Innoen from the global biopharmaceutical company Sciwind Biosciences in 2024. HK Innoen has secured the rights for domestic development and commercialization, and is developing it as a treatment for obesity and diabetes.